Albireo Pharma (ALBO) Reports Q1 Loss of $0.15, Miss on Revenues

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. TENB
7. CMG
8. KLAC
9. BIIB
10. PPG

Go back to Albireo Pharma (ALBO) Reports Q1 Loss of $0.15, Miss on Revenues

Albireo Pharma (ALBO) Reports First Patient Enrollment in Phase 3 PFIC Trial of A4250

May 16, 2018 8:31 AM EDT

Albireo Pharma, Inc. (NASDAQ: ALBO) today announced the first patient has been enrolled in PEDFIC-1, a Phase 3 clinical trial of lead product candidate A4250, an ileal bile acid transporter (IBAT) inhibitor being studied for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC).

A PFIC diagnosis for our children was shocking and devastating, and we quickly found out that current treatment options are inadequate, said Kristen and Michael Busby of New York, parents of two children with PFIC. We applaud all research in this area, and it is great news... More